Introduction

Whether IgA nephropathy (IgAn) is a single disease remains of debate, because of its variable clinical and pathogenic presentation, disease progression and complications, geographic and sex variation, and treatment response. It can be argued that IgAn is a glomerular pattern rather than disease because of its simple definition (1). Indeed, 5%–10% of kidney samples from the autopsies of trauma victims or people without a renal history showed mesangial IgA deposition (2–4), and 14%–17% of kidney donors without a renal history had evidence of mesangial IgA deposition with or without C3 (5).

IgAn is the most frequent biopsy-proven primary GN; however, its geographic prevalence varies. A systematic review suggests IgAn has an incidence of at least 2.5 per 100,000 in adults worldwide (6). However, the prevalence of IgAn is much higher in East Asia compared with North America and Europe (6,7). This is partly explained by the increased performance renal biopsies and national urine screening programs in East Asia. In Japan, Korea, and Taiwan, there is annual urinalysis as a part of a health check program that encourages the early referral of individuals, even with persistent microscopic hematuria with or without mild proteinuria, which increases the frequency of IgAn diagnosis (7,8). A wide indication for a renal biopsy, even in individuals with microscopic hematuria, resulted in the identification of a large number of asymptomatic urinary abnormalities caused by IgAn, not only in Asia but also in Europe (9–11), suggesting the true prevalence of IgAn globally is underreported. An observational study of renal biopsies in patients with hematuria without overt proteinuria reported a high proportion of IgAn (62%), and 31% of these patients with IgAn have active glomerular lesions, including crescent formation (9). This may be a part of the reason why persistent isolated microscopic hematuria is a risk for ESKD (12).

IgAn in East Asia has a male to female ratio of 1:1 or <2:1, which is different from that in Europe and the United States. and reports ratios as high as 6:1 (13–15). This strongly indicates that environmental and/or genetic factors may have certain roles in the pathogenesis of IgAn. The contribution of race to the etiology of ESKD in patients with IgAn has been reported. Barbour et al. reported that individuals of Pacific Asian origin...
had a significantly increased risk of ESKD, even after adjusting for the effects of known prognostic variables, such as age, eGFR at biopsy, proteinuria, and mean arterial pressure (16). Although this risk may be explained by racial differences, the effects of Asian origin on disease progression may not be explained by specific factors related to IgAn, such as the number of nephrons at birth (17,18).

Differences in the renal progression of male and female patients with IgAn are still controversial. Recent Chinese studies reported that no significant differences were observed in the long-term renal survival of male and female patients, despite matching with prognostic factors such as eGFR and serum uric acid (19-21). Cattran et al. demonstrated that, in contrast with membranous GN and focal segmental glomerulosclerosis, baseline and follow-up urinary protein and patient sex did not influence IgAn progression (22). However, this is in contrast with a large meta-analysis (23). A recent study from Estonia has reported that renal progression occurs faster in males than in females, with a correlation between a higher Oxford MEST score and disease progression in male patients (24). It is now widely accepted that galactose-deficient IgA1 (Gd-IgA1) and Gd-IgA1 immune complex formed with autoantibodies against GdIgA1 are key effector molecules in IgAn, and are thus referred to as prognostic markers (25-28). A recent report indicates a significant difference in Gd-IgA1 level between United Kingdom and Chinese patients with IgAn and healthy subjects (29). Enzyme core 1 synthase, glycoprotein-N-acetylgalactosamine 3-β-galactosyltransferase (C1GALT1) is known to catalyze the transfer of galactose UDP-Gal to N-acetylgalactosamine O-linked esters of threonine and serine residues of IgA1 (30). The C1GALT1 gene is strongly associated with Gd-IgA1 level in both populations without sex bias (29,31); however, a different lead single nucleotide polymorphism (SNP) of C1GALT1 and a novel genetic interaction with GALNT12, which is a key enzyme for the O-glycosylation of N-acetylglactosamine may exist only in Chinese patients (31), suggesting serum elevation of Gd-IgA1 is the result of different regulation with the same enzyme in different races. Berthoux et al. reported the serum levels of autoantibody against Gd-IgA1 are associated with IgAn progression (32). However, this French cohort comprised 75% male patients with IgAn, and the absolute renal risk for dialysis or death was correlated with a high number of male patients. Such a male-dominant elevation of antiglycan antibody with poor prognosis was not observed in Japanese patients (33). Therefore, the prognostic value of the serum level of anti-Gd-IgA1 antibody should be carefully evaluated in multiethnic cohorts, such as via an international collaborative study of an International IgAn prediction tool (34).

Clinical Features and Practice of IgAn in Japan and Europe: Results from An International Survey

To further understand the geographic heterogeneity of IgAn, a recent clinical survey of the management of IgAn in Europe and Japan through a collaborative study between the Japanese Society of Nephrology and the European Renal Association-European Dialysis Transplantation Association (ERA-EDTA) may be helpful. A retrospective analysis comprising patients with biopsy-proven IgAn from 2016 to 2017 was performed to compare the clinical and therapeutic features of European countries (Europe) (n=437) and Japan (n=470). The questionnaire was distributed to leader institutions in both regions (24 from Europe and 24 from Japan) after approval from the ethics committee at each institution. Patients with IgAn were randomly selected from each institution for data collection.

Urinary Abnormalities and Renal Function before Renal Biopsy

The frequency of history of macrohematuria was similar between Europe and Japan (Table 1). Hematuria was rarely (3%-5%) associated with acute gastrointestinal disorders in both cohorts (Figure 1). However, the frequency of hematuria coincident with an upper respiratory tract infection was higher (23% and 30% in Europe and Japan, respectively) (Figure 1), without significant differences between the two cohorts. Many Japanese practitioners required a history of proteinuria (>300 mg/day) detected twice on urinalyses, performed more than 3 months apart, for the indication of renal biopsy. The rate of a renal biopsy being performed <1 year after the initial detection of proteinuria was higher in Europe (Table 1). The ratio of nephrotic syndrome before renal biopsy was much higher in Europe compared with Japan (21% and 4%, respectively). Moreover, multiple renal abnormalities were discovered during an annual health check-up in Japan (Table 1), and Japanese patients with IgAn were diagnosed at a relatively early stage.

In Europe, 21% of patients with IgAn had a renal biopsy an increase in serum creatinine (Table 1). The frequency of preserved eGFR at the time of renal biopsy (>60 ml/min per 1.73 m²) was low in Europe (55%) compared with Japan (71%). Moreover, 20% of the European cohort had an acute renal injury (Table 1). IgAn possibly progressed in Europe at the time of the renal biopsy.

Gastrointestinal Disorders and Upper Respiratory Tract Infections Coincident with Urinary Abnormalities

The frequent occurrence of episodic macroscopic hematuria with a concurrent upper respiratory or intestinal tract infection suggests the mucosal immune system plays an important role in IgAn progression (35,36). The ratio of gastrointestinal complications, such as Crohn’s disease (CD), ulcerative colitis (UC), and celiac disease, were more frequent in Europe compared with Japan (17% vs 1%) (Table 2). Although the serum level of IgA was found to be elevated in patients with CD and UC compared with healthy controls (37), patients with IgAn and an elevated serum IgA at the time of renal biopsy were much less common in Europe compared with Japan (11% vs 34%) (Table 1). Of interest, there were no clear differences in the coincidence of episodic hematuria and gastrointestinal disorders or upper respiratory tract infections between Europe and Japan (Figure 1).

Differences in Status of Treatment between Europe and Japan

The major treatment options for adult IgAn are the use of renin-angiotensin system inhibitors, corticosteroids, nonsteroidal immunosuppressive agents, tonsillectomy (combined with high-dose intravenous corticosteroids), omega 3 fatty acids (fish oil), and antiplatelet agents. Because several clinic
studies have confirmed a favorable effect of tonsillectomy (38), it has now become a common treatment option in Japan. In fact, approximately 53% of patients with IgAn in Japan underwent a tonsillectomy (Figure 2). Renin-angiotensin system inhibitors are a common treatment option in both Europe and Japan, conversely, major therapeutic differences between Europe and Japan are reported on the use of high-dose intravenous corticosteroids and oral corticosteroids (Figure 3). Note that 60% of Japanese patients with IgAn were treated with corticosteroids. Although several reports suggest a risk of adverse events after the use of corticosteroids in patients with IgAn (39), most patients with IgAn in Japan had completed corticosteroids during the 2-year study period, hence suggesting a rather safe treatment (Table 3). Although a clinical study in a large cohort in Japan and a recent meta-analysis of 14 studies in mainly Asian countries confirmed a favorable effect of tonsillectomy (38,40), good outcomes of tonsillectomy for IgAn were not reported in European studies (41–43). Meanwhile, the novel targeted-release formulation of budesonide targeting small intestine was shown to reduce proteinuria in patients with IgAn in European countries (44). There are epidemiologic differences between Asia and European countries, such as sex ratios and frequency of intestinal complications, including CD, UC, and celiac disease. Thus, there is a possibility the effectiveness of tonsillectomy may depend on racial differences. However, the limited number of patients receiving tonsillectomy in Europe because of IgAn and not for ear, nose, and throat indications does not allow a comparison between the continents (41,43). Despite negative results (41,42) in small European studies, a report from Germany indicated that many patients with IgAn in the tonsillectomy group had progressive disease (serum creatinine >2 mg/dl) (42). Meanwhile, a Hungarian report showed the positive effects of tonsillectomy in 98 White patients with IgAn (45). Thus, further basic and clinical studies are required to determine the efficacy of tonsillectomy in different races. The European ear, nose, and throat guidelines do not support tonsillectomy in patients without repeated episodes of tonsillitis, hence this procedure remains not easily applicable in Europe.

### Table 1. Clinical features of patients with IgA nephropathy obtained by questionnaire surveys in Europe and Japan

| Feature                                      | Europe | Japan |
|----------------------------------------------|--------|-------|
| Numbers                                      | 437    | 470   |
| Age, yrs                                     | 43.5   | 40.1  |
| Sex, male/female, %                         | 67/33  | 41/59 |
| Ethnicity                                    | 93% White, others from Asian, American and African | All Japanese |
| History and persistent macrohematuria, %     | 23     | 29    |
| Time between first detection of hematuria and renal biopsy (<1 year), % | 54     | 34    |
| History of single detection of proteinuria (>1 g/day), % | 22     | 11    |
| History of proteinuria (>300 mg/day) in twice detections greater than 3 months apart before renal biopsy, % | 40     | 72    |
| Nephrotic syndrome before renal biopsy, %    | 21     | 4     |
| Time between first detection of proteinuria and renal biopsy (<1 year), % | 72     | 40    |
| Detection of increase of serum creatinine before renal biopsy, % | 21     | 13    |
| eGFR at the time of renal biopsy (>60 ml/min per 1.73m²), % | 55     | 71    |
| Significant (>20%) decrease in GFR at time of biopsy over the previous months, % | 20     | 8     |
| Elevated serum IgA at the renal biopsy, %   | 11     | 34    |
| Family history of kidney disease / family history of IgAn, % | 7 / (IgAn: 2) | 16 / (IgAn: 2) |
| Renal abnormalities were discovered as part of a systematic screening program, % | 10     | 74    |

**IgAn, IgA nephropathy.**

**Figure 1.** The ratio of episodic hematuria coincident with an acute gastrointestinal disorder or upper respiratory tract infection. There are no clear differences between the ratio of episodic hematuria coincident with an acute gastrointestinal disorder between Europe and Japan. However, the ratio of episodic hematuria coincident with an upper respiratory tract infection was relatively high in both Europe and Japan (23% vs 30%, respectively). Euro, Europe.

**Potential Underlying Molecular Mechanisms in Race/Sex difference in IgAn**

**Mechanisms Related to Intestinal Disorders**

This clinical survey highlights the similarities and differences in European and Japanese patients with IgAn and clinical care. The hallmark manifestation of IgAn is macrohematuria, which often coincides with an upper respiratory tract infection and is indicative of the pathogenic roles of the nasopharyngeal and bronchial mucosae. However, the survey also revealed obvious differences in the frequency
of gastrointestinal complications between nations, including inflammatory bowel disease (IBD) and celiac disease in European patients with IgAn (Europe 17%; Japan 1%, Table 2). IBD, including CD and UC, have been considered disorders that primarily affect patients of European ancestry (46,47). Celiac disease is an autoimmune enteropathy triggered by dietary gluten in genetically susceptible individuals, especially of European ancestry (48). However, the incidence of IBD and celiac disease is increasing in non-European and non-White populations (49–51). Considering the altered etiology of IBD and celiac disease, the clear geographic difference in the prevalence of intestinal diseases in this survey may be more than coincidence and suggests a pathogenetic connection between gut inflammation in IgAn and the heterogeneity of European patients with IgAn.

Transgenic mouse models of IgAn overexpress a ligand for lymphotoxin β receptor or B cell–activating factor (BAFF), which are both essential molecules for IgA class switching and intestinal IgA production by resident IgA+ plasma cells, and thereby demonstrate the overproduction of polymeric IgA in the intestinal mucosa results in high serum levels of IgA (approximately 100 times higher) and IgAn disease phenotypes (37,52). The polymeric immunoglobulin receptor (pIgR) is the key molecule for the luminal trafficking of mucosal dimeric IgA in the intestine and upper respiratory tract (53,54). Excessive IgA remaining in the intestinal lamina propria is therefore considered to be the result of overwhemed pIgR, which leads to the leakage of mucosal IgA into the circulation of transgenic mice. Serum IgA elevation has been observed in patients with CD and UC (37,55), suggesting intestinal inflammation may interfere with IgA trafficking by pIgR. Intestinal inflammation in patients with IgAn with celiac disease may share the same mechanism of the mesangial deposition of intestinal IgA (56). Interestingly, certain Swedish reports suggest 33% of patients with IgAn have a mucosal sensitivity to gluten without the clinical manifestations of celiac disease (57,58). Furthermore, antigliadin antibodies were detected in association with high levels of IgA immune complexes in Italian patients with IgAn (59). More recently, a French IgAn cohort without the manifestations of celiac disease exhibited elevated serum antigliadin antibody (60), suggesting even subclinical intestinal inflammation may lead to glomerular IgA. A pathogenic mechanism was proposed using a humanized mouse model of IgAn, the α1KICD89Tg mouse, that expresses human IgA1 and the human myeloid CD89 IgA Fc receptor. Under a normal diet, in their serum these mice displayed IgA1 antibodies to gliadin complexed with soluble CD89. A gluten-free diet resulted in a decrease of mesangial IgA1 deposits and hematuria. Disease severity depended on gluten and CD89, as shown by the reappearance of IgAn features in mice fed a gluten diet (61). However, a serological link with antigliadin antibody was absent in patients with IgAn in Japan and the United States (62,63). Moreover, most patients with IgAn do not usually complain of any gastrointestinal disorders,

Table 2. Complications accompanied by IgA nephropathy

| Complication                      | Europe (%) | Japan (%) |
|-----------------------------------|------------|-----------|
| Gastrointestinal complications    |            |           |
| Celiac disease                    | 2          | 0         |
| Crohn’s disease                   | 2          | 0.90      |
| Ulcerative colitis                | 3          | 0         |
| Irritable bowel syndrome          | 4          | 0         |
| Chronic, nondefined               | 6          | 0.20      |
| gastrointestinal symptoms         | 17         | 1         |
| Total                             |            |           |
| Others                            |            |           |
| Periodontitis                     | 0.20       | 4         |
| Atopic dermatitis                 | 1          | 6         |
| Bronchial asthma                  | 4          | 3         |

Figure 2. History of recurrent tonsillitis and tonsillectomy. Although recurrent tonsillitis is relatively common in Japanese patients with IgA nephropathy (IgAn), the ratio of tonsillectomy because of recurrent tonsillitis is similar between Europe and Japan. However, tonsillectomy is a common treatment option in Japan, and approximately 53% of Japanese patients with IgAn underwent a tonsillectomy.
indicating certain specific environmental factors may facilitate such a link in European patients. In a direct comparison with patients with IgAn from various continents, abnormal levels of IgA directed against various alimentary antigens were found to be less frequent in Japanese versus European patients (0%–16% versus 19%–28%, respectively for IgA against different alimentary components) (64). It is known that IgA transcytosis and trafficking by pIgR in mucosal cells are strikingly augmented by estradiol (65). This is thought to be a part of the reason why female patients are more resistant against pneumonia after trauma (66–69). In this regard, the presence of a sex-hormone-based difference in mucosal IgA trafficking should be carefully examined for sex bias in European patients with IgAn.

**Table 3. Long-term maintenance of oral corticosteroids**

| Time     | Europe (%) | Japan (%) |
|----------|------------|-----------|
| 3–6 months | 31          | 11        |
| 6 months to 1 year | 32          | 47        |
| 1–2 years  | 21          | 36        |
| 2–3 years  | 9           | 5         |
| 3–5 years  | 6           | 0         |
| >5 years   | 1           | 1         |

**Figure 3. Differences in the status of treatment between Europe and Japan.** Treatment with renin-angiotensin system (RAS) inhibitors is common in both Europe and Japan. There are major differences in the use of high-dose intravenous corticosteroids and oral corticosteroids between Europe and Japan.

**Immune Crosstalk between Nasopharyngeal/Bronchial- and Gut-associated Mucosal Tissues**

A recent genome-wide association study (GWAS) on IgAn demonstrated a disease association with loci related to molecules responsible for intestinal immunity, maintenance of the intestinal barrier and IBD, reinforcing the importance of interstitial immune response in IgAn (70–72). However, most of the molecules in these mucosal immune-related loci fulfill the immunologic function not only of gut-associated lymphoid tissue (GALT) but also nasopharyngeal/bronchial-associated lymphoid tissues (NALT/BALT), although much remains to be elucidated about NALT/BALT-mediated regulation of IgA immunity compared with that of GALT.

Although a genetic association at the variants rs2412971, intronic in HORMAD2 at 22q.12.2 was reported in GWAS for IgAn involving Han Chinese and European cohorts (70–72), a GWAS for tonsillectomy revealed that the same SNP, rs2412971, is robustly associated with an increased risk of requiring a tonsillectomy (73), which is suggestive of HORMAD2-related susceptibility of infection or a hyperimmune reaction in the palatine tonsil. Indeed, on the telomeric side of HORMAD2, the two nearest neighboring genes, LIF and OSM, encode cytokines that are members of the IL-6 family and thus may play a role in the hyperimmune response or inflammation (73,74). Note that the GWAS for tonsillectomy demonstrated that rs2412971 is associated with a decreased risk of CD and IBD in the European population (75–77), revealing opposing effects of risk loci for IgAn in IBD. Epidemiologic studies with nationwide cohorts and a related meta-analysis primarily from European studies revealed a tonsillectomy is associated with an increased likelihood of developing CD and IBD (78–80). These results call into question a direct influence of tonsillectomy on GALT. A Danish nationwide cohort study demonstrated that a history of tonsillectomy in first- and second-degree relatives increases an individual’s risk of IBD (78), suggesting shared hereditary or environmental factors.

There is growing evidence of physiologic and pathologic crosstalk in IgA immunity between NALT/BALT and GALT (81,82) or mucosa and nonmucosal tissues (83). After intranasal immunization with inactive cholera toxin, lung dendritic cells stimulate the retinoic acid–dependent upregulation of α4β7 and CCR9 gut-homing receptors on local IgA-expressing B cells (81). The migration of these B cells to the
gut results in IgA-mediated protection against an oral challenge with active choler toxin. Such homing plasticity of IgA^+ B cells in NALT/BALT may underlie this crosstalk, although GALT-oriented IgA^+ B cells home more efficiently to GALT, but not to spleen or NALT/BALT (84,85).

**APRIL/BAFF Balance in B Cell Regulation in IgAn**

Different GWAS for common infections and infection-associated procedures in patients with a European ancestry demonstrated certain independent genome-wide associations with tonsillectomy. These include HLA and genes of the TNF/receptor superfamily ligands, such as TNFSF13B and TNFRSF13B, which encode BAFF and the transmembrane activator and cyclophilin ligand interactor, respectively (86). BAFF and a proliferation-inducing ligand (APRIL) are members of the TNF superfamily, and are essential cytokines to IgA class-switch recombination and B cell differentiation and maturation in the mucosa, although pathophysiologic role sharing between APRIL and BAFF largely remains unknown (87). Transmembrane activator and cyclophilin ligand interactor is one of the shared receptors of BAFF and APRIL. Although the overexpression of BAFF leads to the intestinal accumulation of IgA^+ plasma cells and subsequent murine IgAn (52), several GWAS carried out in patients with IgAn identified a strong associated loci at TNFSF13 at 17p13 encoding APRIL, but not TNFSF13B (BAFF) (71,72). Moreover, APRIL targeted antibodies (88,89), but not BAFF (paper in revision), dramatically improved kidney injury as evidenced by decreased proteinuria and mesangial IgA deposition in spontaneous murine IgAn models (grouped ddY). Moreover, the serum levels of APRIL were correlated with the serum levels of GdIgA1 and IgAn prognosis (90,91). Such experimental and clinical results support the idea that IgAn is an APRIL-mediated disease rather than a BAFF-mediated disease.

The tonsillar expression of APRIL in patients with IgAn is significantly higher than in those with chronic tonsillitis (92). Such tonsillar APRIL expression involves germinal center B cells (92). Toll-like receptor (TLR)-mediated microbial sensing plays a critical role in IgA production in the mucosa via APRIL/BAFF activation (87). We previously reported that a specific SNP of TLR9 that recognizes the unmethylated DNA of microorganisms is significantly associated with the pathologic severity of IgAn (93). The expression of TLR9 in the tonsils is related to reduced serum IgA and GdIgA1 after a tonsillectomy, which represents a treatment response (94,95). Note the persistent stimulation of TLR9 induces APRIL expression in the B cells themselves, even in tonsillar B cells from patients who do not have IgAn (92). Indeed, tonsillar APRIL expression is significantly correlated with TLR9 in patients with IgAn (92). At least in the spontaneous murine IgAn model, TLR9 activation in NALT, but not GALT, is involved in nephritogenic aberrantly glycosylated IgA production and subsequent renal damage (96). The association between TNFSF13 (APRIL) at 17p13 and HOMA-DS2(UFOSM) at 22q12 in an independent population-based GWAS of the serum levels of IgA is worthy of note (97), because LIF/STAT1 signaling is involved in the overproduction of Gd-IgA1 in IgAn (98). These results suggest an aberrant innate immune activation of mucosal TLR9/APRIL in IgAn. Furthermore, in addition to the risk of tonsilllectomy, BAFF is known as a potential biomarker for active IBD and celiac disease (99,100). Further examinations with translational approaches are required to find a core molecular mechanism; however, assessment from the point of APRIL/BAFF balance in the crosstalk between NALT/BALT and GALT may be one of next challenges to explain the heterogeneity of IgAn.

**Disclosures**

Y. Suzuki reports having consultancy agreements with Chinook, Kyowa-Kirin, and Visterra; reports receiving research funding from Astellas Pharma, Baxter, Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Hakko Kirin, Moderna, Ono Pharmaceutical, Retrophin, Sanwa Kagaku Kenkyusho, Sunstar, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Teijin Pharma, Torii Pharmaceutical, and Visterra; reports receiving honoraria from Tanabe Mitsubishi Pharmaceutical company; and reports being a scientific advisor or member of Kidney International and Nephrology. All remaining authors have nothing to disclose.

**Funding**

This study was supported in part by the Study Group on IgA Nephropathy research grant, Grant-in-Aid for Progressive Renal Disease Research, Research on Intractable Disease from the Ministry of Health, Labour and Welfare of Japan grant 20FC1045, and Japan Agency for Medical Research and Development under grant JP21gm0010006.

**Acknowledgments**

We thank the Immunonephrology working group of the ERA-EDTA, chaired by Vladimir Tesar (first Faculty of Medicine, General University Hospital, Department of Nephrology, Charles University, Prague, Czech Republic), Valentina Cocchi, Working Group Coordinator of the ERA-EDTA, and Francesca Trebelli, Electronic Communication Coordinator of the ERA-EDTA. We also thank the nephrology units of 24 Japanese institutions for their survey participation: Ashikaga Red Cross Hospital, Jikei University Daisan Hospital, Jikei University Kashiwa Hospital, Jikei University Katsushika Medical Center, Jikei University School of Medicine, Juntendo University Nerima Hospital, Juntendo University Urayasu Hospital, Kitano Hospital, Kyoto University, Miyazaki University, Nagasaki University, National Hospital Organization Fukuoka-higashi Medical Center, Niigata University, Osaka University, Osaka Medical College, Sendai Shai-kaiboken Hospital, Shimane University, Showa University, St. Marianna University School of Medicine, St. Marianna University Yokohama City Seibu Hospital, Teikyo University, The Tazuke Kofukai Medical Research Institute, Tokyo Women’s Medical University, and Tokyo Metropolitan Health and Medical Treatment Corporation Okubo Hospital.

**Author Contributions**

Y. Suzuki conceptualized the study; H. Suzuki was responsible for data curation; H. Suzuki, R. Monteiro, and Y. Suzuki were responsible for formal analysis; Y. Suzuki was responsible for funding acquisition; H. Suzuki, R. Monteiro, and Y. Suzuki were responsible for investigation; H. Suzuki, R. Coppo, R. Monteiro, and Y. Suzuki were responsible for the methodology; R. Monteiro and Y. Suzuki were responsible for project administration; Y. Suzuki provided supervision; H. Suzuki and Y. Suzuki wrote the original draft; R. Coppo, R. Monteiro, and Y. Suzuki reviewed and edited the manuscript; H. Suzuki, R. Coppo, and R. Monteiro were responsible for validation.
References

1. Berger J, Hinglais N: Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 74: 694–695, 1968
2. Varis J, Rantala I, Pasternack A, Oksa H, Jäntti M, Paunu ES, Pihironen R: Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol 46: 607–610, 1993 https://doi.org/10.1136/jcp.46.7.607
3. Walldherr R, Rambausek M, Duncker WD, Ritz E: Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 4: 943–946, 1989 https://doi.org/10.1093/ndt/4.11.943
4. Suganuma T: Glomerular IgA deposits in an autopsy study. Nippon Jinzo Gakkai Shi 36: 813–822, 1994
5. Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y: Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63: 2286–2294, 2003 https://doi.org/10.1046/j.1522-1755.2003.0062.x
6. McGroan A, Franssen CFM, de Vries CS: The incidence of primary glomerulonephritis worldwide: A systematic review of the literature. Nephrol Dial Transplant 26: 414–430, 2011 https://doi.org/10.1093/ndt/gfr565
7. Schena FP, Nistor I: Epidemiology of IgA nephropathy: A global perspective. Semin Nephrol 38: 435–442, 2018 https://doi.org/10.1016/j.semnephrol.2018.05.013
8. O’Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC: Glomerular disease frequencies by race, sex and region: Results from the International Kidney Biopsy Survey. Nephrol Dial Transplant 33: 661–669, 2018 https://doi.org/10.1093/ndt/gfx189
9. Hoshino Y, Kaga T, Abe Y, Endo M, Wakai S, Tsuchiya K, Nitta H: Renal biopsy findings and clinical indicators of patients with hematuria without overt proteinuria. Clin Exp Nephrol 19: 918–924, 2015 https://doi.org/10.1007/s10157-015-1090-6
10. Power DA, Murhead N, Simpson JC, Nicholls AJ, Horne CH, Catto GR, Edward N: IgA nephropathy is not a rare disease in the United Kingdom. Nephron 40: 180–184, 1989 https://doi.org/10.1159/000183457
11. Petterson E, von Bonsdorff T, Törnroth T, Lindholm H: Nephritus among young Finnish men. Clin Nephrol 22: 217–222, 1984
12. Vivante A, Alek A, Frenkel-Nir Y, Tzur D, Farbel A, Golan E, Chaiter Y, Shohat T, Skorecki K, Calderon-Margalit R: Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA 306: 729–736, 2011 https://doi.org/10.1001/jama.2011.1141
13. Donadio JV, Grande JP: IgA nephropathy. N Engl J Med 347: 736–748, 2002 https://doi.org/10.1056/NEJMra020399
14. Geddes CC, Rauta V, Gronhagen-Riska C, Bartosik LP, Jardine AM, Matthijsen J, Renfrow MB, Novak L, Wyatt RJ, Novak J: Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Int 93: 700–705, 2018 https://doi.org/10.1016/j.kint.2017.10.019
15. Duan ZY, Cai GY, Chen YZ, Liang S, Liu SW, Wu J, Qiu Q, Lin SP, Zhang XG, Chen XM: Aging promotes progression of IgA nephropathy: A systematic review and meta-analysis. Am J Nephrol 38: 241–252, 2013 https://doi.org/10.1159/000354646
16. Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich M, Reich HN: Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int 84: 1017–1024, 2013 https://doi.org/10.1038/ki.2013.210
17. Tsukui N, Kawamura T, Koike K, Konokogi H, Hirano K, Hamaguchi A, Miyazaki Y, Ogura M, Joh K, Utsunomiya Y, Tsuboi N, Shimizu A, Denton KM, Caplin B, Ferlin A, Yin P, Nelson CP, Stanescu H, Samani NJ, Troyanov S, Genes, and Glomerulonephritis Group: The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 23: 2247–2253, 2008 https://doi.org/10.1093/ndt/gmn19
18. Cattran DC, Reich HN, Beanlands HS, Miller JA, Scholte JW, Tsuboi N, Shimizu A, Denton KM, Hughson MD, Kleta R, Yu X, Barratt J: Galactosylation of IgA1 is associated with IgA nephropathy. Kidney Int 82: 790–796, 2012 https://doi.org/10.1038/ki.2012.197
19. Suzuki H, Yasutake J, Matika Y, Tanbo Y, Yamasaki K, Soufe T, Kano T, Suzuki Y: IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-related pathogenesis. Kidney Int 93: 701–703, 2018 https://doi.org/10.1016/j.kint.2017.10.019
20. Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, Caplin B, Ferlin A, Yin P, Nelson CP, Stanescu H, Samani NJ, Kleta R, Yu X, Barratt J: Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol 28: 2158–2166, 2017 https://doi.org/10.1681/ASN.2016091043
21. Mestecky J, Tomana M, Molodezou Z, Julian BA, Suzuki H, Matousovic K, Renfrow MB, Novak J, Wang YN, Zhou XJ, Chen P, Yu GZ, Zhang X, Hou P, Liu LJ, Shi SF, Lv JC, Zhang H: Interaction between GALNT2 and C1GALT1 associates with galactose-deficient IgA1 and IgA nephropathy. J Am Soc Nephrol 32: 545–552, 2021 https://doi.org/10.1681/ASN.2020060823
22. Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomano Y, Julian BA, Novak J: Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23: 1579–1587, 2012 https://doi.org/10.1681/ASN.2011100153
23. Nakamura I, Iwase H, Arai K, Nagai Y, Toma K, Katsumata T, Yuki K, Kubo T, Sano T, Kobayashi Y: Detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients by using synthetic hinge peptide and glycopeptide probes. Nephrol

Race/Sex Differences in IgA Nephropathy, Suzuki et al. 1345
79. Wu MC, Ma KSK, Wang YH, Wei JCC: Impact of tonsillectomy on irritable bowel syndrome: A nationwide population-based cohort study. *PLoS One* 15: e0238242, 2020 https://doi.org/10.1371/journal.pone.0238242

80. Sun W, Han X, Wu S, Yang C: Tonsillectomy and the risk of inflammatory bowel disease: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 31: 1085–1094, 2016 https://doi.org/10.1111/jgh.13273

81. Ruane D, Chorny A, Lee H, Faith J, Pandey G, Shan M, Simoni N, Rahman A, Garg A, Weinstein EG, Oropallo M, Gaylord M, Ungaro R, Cunningham-Rundles C, Alexandropoulos K, Mucida D, Merad M, Cerutti A, Mehandru S: Microbiota regulate the ability of lung dendritic cells to induce IgA class-switch recombination and generate protective gastrointestinal immune responses. *Exp Med* 213: 53–73, 2016 https://doi.org/10.1084/jem.20150567

82. Bemark M, Hazanov H, Strömberg A, Komban R, Holmqvist J, Köster S, Mattsson J, Sikora P, Mehr R, Lycke NY: Limited clonal relatedness between gut IgA plasma cells and memory B cells after oral immunization. *Nat Commun* 7: 12698, 2016 https://doi.org/10.1038/ncomms12698

83. Rojas OL, Pröbstel AK, Porfilio EA, Wang AA, Charabati M, Sun T, Lee DSW, Galicia G, Ramaglia V, Ward LA, Leung LYT, Najić G, Khaleghi K, Garcia N, Li A, Besla R, Naozur J, Cao EY, Chiaranunt P, Burrows K, Robinson HG, Allanach JR, Yam J, Luck H, Campbell DJ, Allman D, Brooks DG, Tomina M, Baumann R, Zamvil SS, Barsacchi S, Baranzini SE, Mackay F, Prat A, Osborne LC, Robbins C, Baranzini SE, Gommerman JL: Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10 [published correction appears in *Cell* 177: 492–493, 2019] Cell 176: 610–624.e18, 2019 https://doi.org/10.1016/j.cell.2018.11.035

84. Brandtzæg P: Mucosal immunity: induction, dissemination, and effector functions. *Scand J Immunol* 70: 505–515, 2009 https://doi.org/10.1111/j.1365-3083.2009.02319.x

85. Brandtzæg P: Secretory immunity with special reference to the oral cavity. *J Oral Microbiol* 5: 20401, 2013 https://doi.org/10.3402/jom.v5i0.20401

86. Tian C, Hromatka BS, Kiefer AK, Eriksson N, Noble SM, Tung JY, Horwitz MS, Winer DA, Mortha E, Cao F, Li A, Besla R, Naouar I, Cao EY, Chiaranunt P, Burrows K, Robinson HG, Allanach JR, Yam J, Luck H, Campbell DJ, Allman D, Brooks DG, Tomina M, Baumann R, Zamvil SS, Barsacchi S, Baranzini SE, Gommerman JL: Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10 [published correction appears in *Cell* 177: 492–493, 2019] Cell 176: 610–624.e18, 2019 https://doi.org/10.1016/j.cell.2018.11.035

87. Zhao Y, Zhu L, Shi SF, Liu JJ, Lv JC, Zhang H: Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. *Medicine (Baltimore)* 95: e3099, 2016 https://doi.org/10.1097/MD.0000000000003099

88. Han SS, Yang SH, Choi M, Kim HR, Kim K, Lee S, Moon KC, Kim JY, Lee H, Lee JP, Jung JY, Kim S, Joo KW, Lim CS, Kang SW, Kim YS, Kim DK: The role of TNF superfamily member 13 in the progression of IgA nephropathy. *J Am Soc Nephrol* 27: 3430–3439, 2016 https://doi.org/10.1681/ASN.2015060677

89. Muto M, Manfoii B, Suzuki H, Joh K, Nagai M, Waki S, Righini C, Maiguma M, Izu S, Tomino Y, Huard B, Suzuki Y: Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy. *J Am Soc Nephrol* 28: 1227–1238, 2017 https://doi.org/10.1681/ASN.2016050496

90. Suzuki H, Suzuki Y, Kitada T, Iizuka M, Yamanaka K, Kanou T, Tsukaguchi H, Novak J, Horikoshi S, Tomino Y: TOLL-like receptor 9 affects severity of IgA nephropathy. *J Am Soc Nephrol* 19: 2384–2395, 2008 https://doi.org/10.1681/ASN.2007121311

91. Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuoka K, Horikoshi S, Novak J, Tomino Y: Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. *PLoS One* 9: e89707, 2014 https://doi.org/10.1371/journal.pone.0089707

92. Nasut D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, Yokoi H, Horikoshi S, Ikeda K, Tomino Y: Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. *Nephrol Dial Transplant* 27: 1090–1097, 2012 https://doi.org/10.1093/ndt/gfr403

93. Kano T, Suzuki H, Makita Y, Fukao Y, Suzuki Y: Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy [published online ahead of print May 5, 2021] *Kidney Int* S0085-2538(21)00467-1

94. Osman W, Okada Y, Kamatani Y, Kubo M, Matsuura K, Nakamura Y: Association of common variants in TNFRSF13B, TNFSF13, and ANXA3 with serum levels of non-albumin protein and immunoglobulin isotypes in Japanese. *PLoS One* 7: e32683, 2012 https://doi.org/10.1371/journal.pone.0032683

95. Yamada K, Huang QZ, Raska M, Reily C, Anderson JC, Suzuki H, Kiriyluk K, Gharavi AG, Julian BA, Willey CD, Novak J: Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy. *Kidney Dis* 6: 168–180, 2020 https://doi.org/10.1159/000505748

96. Zhang P, Liu X, Guo A, Xiong J, Fu Y, Zou K: B cell-activating factor as a new potential marker in inflammatory bowel disease. *Dig Dis Sci* 61: 2608–2618, 2016 https://doi.org/10.1007/s10608-016-4136-z

97. Fabris M, Visentini D, De Re V, Pierroni M, Maieron R, Canezzaro R, Villalta D, Curcio F, De Vita S, Tonutti E: Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease. *Scand J Gastroenterol* 42: 1434–1439, 2007 https://doi.org/10.1080/0300365520701452225

**Received** May 3, 2021 **Accepted** May 24, 2021